Russell Steven Jon 4/A

What Happened

• Russell Steven Jon, Chief Medical Officer of Beta Bionics (BBNX), received a derivative equity award on 2026-02-27 covering 91,520 shares. The grant was reported at $0.00 (no cash paid at grant) and is a derivative security (option/award), not an open-market purchase or sale. The company filed an amended Form 4 on 2026-03-13 to correct the number of shares reported in the original Form 4 filed on 2026-03-03.

Key Details

• Transaction date: 2026-02-27 (reported via amended Form 4 filed 2026-03-13).
• Transaction type/code: Grant/Award (A) of a derivative security.
• Shares/options granted: 91,520; reported price: $0.00 (no cash paid).
• Vesting: Shares subject to the option vest in 36 equal monthly installments measured from March 1, 2026 (Footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Original Form 4 was filed on 2026-03-03; an amended Form 4 was filed 2026-03-13 to correct the reported share count.

Context

• This was a grant of a derivative award (likely options or RSUs) rather than an exercised option or a sale. The vesting schedule means the award will convert to owned shares gradually over three years, subject to continued service and any plan terms. Grants are common for compensation and do not by themselves indicate buying/selling sentiment.